Early, validated signal
We surface physician-validated, commercialization-ready cardiovascular companies early, often before they are broadly known.
NuPulse surfaces physician-validated, commercialization-ready companies early, with the clinical evidence acquirers actually use to act.
We surface physician-validated, commercialization-ready cardiovascular companies early, often before they are broadly known.
The clinical data and KOL conviction the major cardiovascular strategics actually use to act.
NuPulse selectively partners with strategic industry leaders to help identify, build, and commercialize technologies aligned with future market needs.
A single relationship, with physician involvement, into a national network and a curated cardiovascular pipeline.
Contribute independent clinical insight to the evaluation of emerging cardiovascular technologies and, where appropriate, participate in separately structured investment opportunities.
Capital, candid physician assessment, and help positioning the company for the buyer most likely to acquire it.
Deal-by-deal SPV syndication into cardiovascular companies our physician network has already evaluated.
An external view of physician-validated cardiovascular companies as they become relevant to your portfolio.
We welcome conversations with founders, investors, physicians, and strategic partners in cardiovascular and electrophysiology medtech.
Email usMiami, Florida